Cantor Fitzgerald assumed coverage of Arcellx (ACLX) with a Neutral rating and $88 price target The shares have performed well of late and are now approaching fair value, the analyst tells investors in a research note. The firm thinks anito-cel’s profile is differentiated on safety and that efficacy in the same ballpark as Carvykti with favorable deliverability will enable it to be very competitive against Carvykti despite it coming to the market four years later.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACLX:
- Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Efficacy, Safety, and Financial Position
- Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval
- 3 Stocks to Buy Now, According to the Technical Analysis
- Promising Clinical Outcomes and Low Toxicity Profile Position Anito-cel as a Leading Therapy for Relapsed/Refractory Multiple Myeloma
- Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs